EGFR and non-small cell lung carcinoma: Several anti-EGFR agents, including monoclonal antibodies and small molecule tyrosine kinase inhibitors have been approved by the US Food and Drug Administration for the treatment of patients with advanced epithelial tumours, including non-small-cell lung cancer (NSCLC), colorectal, head and neck, pancreatic and breast cancer (Modjtahedi and Essapen, 2009).